Overview
GMED market data
Price History
GMED price chart · 1M
- O
- 79.37
- H
- 79.77
- L
- 76.51
- C
- 76.69
- Vol
- 128,594.00
Daily history from Jan 4, 2016
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $79.37
- Previous Close
- $78.87
- Day High
- $79.77
- Day Low
- $76.51
- 52 Week High
- $100.99
- 52 Week Low
- $58.39
- 7 Day Return
- +2.69%
- 30 Day Return
- +1.89%
- 90 Day Return
- +0.85%
- 1 Year Return
- +30.84%
- Daily Notional Volume
- $9.9M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 19.14 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $3.92 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.97 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 17.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $56.96 – $101.40 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- $103.23 Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $10.2B · P/B 2.57 · P/S 3.26.
Company News
10 captured
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/YZacks Investment Research ·
Reasons to Hold Veeva Systems Stock in Your Portfolio for NowZacks Investment Research ·
Is it the Right Time to Add Phibro Stock to Your Portfolio?Zacks Investment Research ·
Smith+Nephew Launches CARTIHEAL Implant Across Key European MarketsZacks Investment Research ·
Smith+Nephew Launches EVOS PELVIC System to Advance Trauma CareZacks Investment Research ·
Veeva Unveils Falcon Router to Streamline Biopharma Case RoutingZacks Investment Research ·
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for NowZacks Investment Research ·
Is This the Right Time to Add DGX Stock to Your Portfolio?Zacks Investment Research ·